Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study

Expert Opinion on Biological Therapy

Volumn 18, Issue , 2018, Pages 61-69

  Wu, Xiaoning ^a   Shi, Yiwen ^a   Zhou, Jialing ^a   Sun, Yameng ^a   Piao, Hongxin ^b   Jiang, Wei ^c   Ma, Anlin ^d   Chen, Yongpeng ^e   Xu, Mingyi ^f   Xie, Wen ^g   Cheng, Jun ^g   Xie, Shibin ^h   Shang, Jia ⁱ   Cheng, Jilin ^j   Xie, Qing ^k   Ding, Huiguo ^l   Zhang, Xuqing ^m   Bai, Lang ⁿ   Zhang, Mingxiang ^o   Wang, Bingqiong ^a   Chen, Shuyan ^a   Ma, Hong ^a   Ou, Xiaojuan ^a   Jia, Jidong ^a   You, Hong ^a   more..

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b YANBIAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h SUN YAT SEN UNIVERSITY   (China)

ⁱ ZHENGZHOU UNIVERSITY   (China)

^j SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^k SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^l CAPITAL MEDICAL UNIVERSITY   (China)

^m THIRD MILITARY MEDICAL UNIVERSITY   (China)

ⁿ SICHUAN UNIVERSITY   (China)

^o Sixth People s Hospital of Shenyang   (China)

more..

Author keywords

Hepatitis B virus; hepatocellular carcinoma; immune regulator; liver cirrhosis; thymosin alpha 1 Ta 1

Indexed keywords

CREATININE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; SERUM ALBUMIN; THYMOSIN ALPHA1; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHILD PUGH SCORE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DISEASE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; ESOPHAGUS VARICES; FEMALE; HUMAN; IMMUNOREGULATION; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOPROLIFERATIVE NEOPLASM; NONPARAMETRIC TEST; OPEN STUDY; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SEROCONVERSION; SUSTAINED VIROLOGIC RESPONSE; ANALOGS AND DERIVATIVES; CHRONIC HEPATITIS B; CLINICAL TRIAL; COMPLICATION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TUMOR; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THYMALFASIN; TREATMENT OUTCOME;

EID: 85051057290     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2018.1451511     Document Type: Article

References (26)

1. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261–283
2. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398
3. Ancell CD, Phipps J, Young L., Thymosin alpha-1. Am J Health Syst Pharm. 2001;58:879–885; quiz 886–878
4. Tuthill C, Rios I, McBeath R., Thymosin alpha 1: past clinical experience and future promise. Ann N Y Acad Sci. 2010;1194:130–135
5. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385–1396
6. Dirchwolf M, Podhorzer A, Marino M, et al. Immune dysfunction in cirrhosis: distinct cytokines phenotypes according to cirrhosis severity. Cytokine. 2016;77:14–25
7. Marquez M, Fernandez-Gutierrez C, Montes-de-Oca M, et al. Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis. Clin Exp Immunol. 2009;158:219–229
8. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9:593–608
9. Sugahara S, Ichida T, Yamagiwa S, et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol Res. 2002;24:346–354
10. Chan HL, Tang JL, Tam W, et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther. 2001;15:1899–1905
11. Yang Y-F, Zhao W, Zhong Y-D, et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res. 2008;77:136–141
12. Kim BH, Lee Y-J, Kim W, et al. Efficacy of thymosin alpha-1 plus peginterferon alpha-2a combination therapy compared with peginterferon alpha-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Scand J Gastroenterol. 2012;47:1048–1055
13. Lim SG, Wai C-T, Lee YM, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11:245–253
14. Zhang YY, Chen EQ, Yang J, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J. 2009;6:63
15. Naylor PH, Mutchnick MG. Immunotherapy for hepatitis B in the direct acting antiviral era: reevaluating the thymosin alpha1 efficacy trials in the light of a combination therapy approach. J Viral Hepat. 2018;25:4–9
16. Giacomini E, Severa M, Cruciani M, et al. Dual effect of Thymosin alpha 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists. Expert Opin Biol Ther. 2015;15(Suppl 1):S59–S70
17. Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339–345
18. Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;65:1438–1450
19. Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int. 2015;35(Suppl 1):78–81
20. Rockey DC. Liver fibrosis reversion after suppression of hepatitis B virus. Clin Liver Dis. 2016;20:667–679
21. Lee HW, Lee JI, Um SH, et al. Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. J Gastroenterol Hepatol. 2008;23:729–735
22. Qiu SJ, Zhou ZG, Shen F, et al. A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection–first announcement of the protocol. Expert Opin Biol Ther. 2015;15(Suppl 1):S133–S137
23. Garaci E, Pica F, Rasi G, et al. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol. 2000;22:1067–1076
24. Shuqun C, Mengchao W, Han C, et al. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology. 2004;51:1445–1447
25. Shuqun C, Mengchao W, Han C, et al. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology. 2006;53:249–252
26. Garaci E, Pica F, Serafino A, et al. Thymosin alpha1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci. 2012;1269:26–33